Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer

An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15–20% have basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but chemoresistance is a common clinical problem...

Full description

Bibliographic Details
Main Authors: Narmeen S. Rashid, Nicole S. Hairr, Graeme Murray, Amy L. Olex, Tess J. Leftwich, Jacqueline M. Grible, Jason Reed, Mikhail G. Dozmorov, J. Chuck Harrell
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Translational Oncology
Subjects:
Breast cancer
TNBC
KPT-330
GSK2126458
XPO1
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321002278

Similar Items

Similar Items